MedPath
Found 30 clinical trials|View Analysis
Sort by:

13-cis Retinoic Acid (Isotretinoin) and Sperm Production

Phase 4
Not yet recruiting
Conditions
Men with Infertility
Interventions
Drug: Isotretinoin
Drug: Control group (placebo)
First Posted Date
2024-11-20
Last Posted Date
2024-11-25
Lead Sponsor
University Hospital, Strasbourg, France
Target Recruit Count
100
Registration Number
NCT06698263
Locations
🇫🇷

CECOS Alsace Strasbourg, Schiltigheim, France

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Phase 1
Completed
Conditions
High-risk Neuroblastoma
Interventions
First Posted Date
2022-05-13
Last Posted Date
2024-10-04
Lead Sponsor
BeiGene
Target Recruit Count
8
Registration Number
NCT05373901
Locations
🇨🇳

Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, Shanghai, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

🇨🇳

The Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Phase 2
Conditions
Tuberculosis
Interventions
Combination Product: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)
Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
Combination Product: 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
Combination Product: All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
Other: The standard therapy
First Posted Date
2021-10-14
Last Posted Date
2021-10-14
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
250
Registration Number
NCT05077813
Locations
🇪🇬

Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt

🇸🇦

Ministry of health. First health cluster, Riyadh, Riaydh, Saudi Arabia

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Phase 3
Conditions
Breast Cancer Female
Interventions
First Posted Date
2021-08-23
Last Posted Date
2021-08-23
Lead Sponsor
Mahmoud Ramadan mohamed Elkazzaz
Target Recruit Count
160
Registration Number
NCT05016349

Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.

Phase 4
Conditions
Post COVID-19 Anosmia (Loss of Smell)
Interventions
Drug: Aerosolized 13 cis retinoic acid plus Vitamin D
Other: Standard therapy
Drug: Aerosolized All trans retinoic acid plus Vitamin D
First Posted Date
2021-08-12
Last Posted Date
2021-11-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
10000
Registration Number
NCT05002530
Locations
🇨🇳

Quan Liu, Foshan, Guangdong, China

🇪🇬

Tamer Haydara, Kafr Ash Shaykh, Kafr Elshiekh, Egypt

🇸🇦

Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia

Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.

Phase 1
Conditions
Covid19 Vaccine
Interventions
Combination Product: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine
Drug: Oral 13 cis retinoic acid
Drug: Aerosolized 13 cis retinoic acid
Combination Product: 13 cis retinoic acid doses orally in combination with spike protein based vaccine
First Posted Date
2021-01-29
Last Posted Date
2021-06-02
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
360
Registration Number
NCT04730895

Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?

Phase 4
Conditions
Covid19
Interventions
Drug: The standard therapy
Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone
First Posted Date
2020-11-10
Last Posted Date
2020-11-10
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
1000
Registration Number
NCT04623385

Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)

Phase 2
Conditions
Covid19
Interventions
Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg
First Posted Date
2020-10-08
Last Posted Date
2020-10-26
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
360
Registration Number
NCT04578236

Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19

Phase 2
Conditions
Covid19
First Posted Date
2020-10-06
Last Posted Date
2020-10-06
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
45
Registration Number
NCT04577378
Locations
🇪🇬

Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt

Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment

Phase 2
Conditions
COVID-19
Interventions
Other: Placebo
Drug: Aerosolized 13 cis retinoic acid
Drug: Aerosolized All trans retinoic acid
First Posted Date
2020-05-20
Last Posted Date
2020-10-27
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
360
Registration Number
NCT04396067
© Copyright 2025. All Rights Reserved by MedPath